Investigation of Analgesic and Anti-inflammatory Effects of Beta-adrenergic Antagonist Propranolol
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Change From Baseline in Mechanical Pain Threshold During Infusion in Non-Inflamed Skin
研究概览
简要总结
Previous studies have shown that the beta-adrenergic system plays a role in processing pain and the expression of hyperalgesia. Recent studies have investigated the analgesic effects, and potential anti-hyperalgesic effects (using a model of opioid induced (OIH) hyperalgesia) of propranolol, a beta adrenergic antagonist. We plan to further investigate the analgesic effects, and the potential anti inflammatory effects, of propranolol and compare those effects to alfentanil, an opioid of known effect, and placebo
详细描述
This study is a double blind-placebo controlled study in which subjects will be exposed to propranolol infusion during one study day, the opioid alfentanil on another day, and placebo infusion during a third study day. The infusion order will be randomized, and the participant and individual conducting the pain testing will both be blinded to the treatment.
Propranolol, alfentanil, and placebo infusions will be administered intravenously using a computer-controlled infusion pump that can be set to accurately administer a target plasma concentration of drug.
On one study day subjects will receive propranolol at a target concentration of 30ng/ml over 3 hours time. On another study day subjects will receive 100ng/ml alfentanil over 3 hours, and on a third study day subjects will receive placebo (normal saline) using a computer-controlled infusion paradigm.
Sites to be evaluated for response to propranolol and placebo will be established in 2 ways. One will use ultraviolet B (UVB) exposure to create a "sunburn" causing inflammation and pain. The other will be a model of acute injury using an array of micro-needles.
Means of evaluation of injured, and non-injured sites will be pain testing (heat and mechanical pain thresholds will be established), interstitial fluid sampling for detection of pro-inflammatory, and pro-nociceptive cytokines, and laser doppler evaluation of tissue perfusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18-65 2) Skin type II-IV according to classification of Fitzpatrick 3) Willing and able to sign an informed consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization and to comply with study procedures
排除标准
- •History of acute or chronic illness that contraindicate the use of propranolol, may hinder study procedures, or confuse interpretation of the data (e.g. cardiac, dermatological, neurological, psychiatric or addictive diseases) 2) Clinically significant cardiovascular, pulmonary, hepatic or renal diseases 3) Pregnant or breast-feeding 4) Intake of prescription drugs with anti/pro-inflammatory action 5) Intake of prescription drugs with anti/pro-analgesic action 6) Inability to abstain from any anti/pro-inflammatory, or analgesic drugs 48 hours before, or during the study session 7) Inability to obtain at least 6 hours of sleep during the night preceding the study session 8) Known sensitivity or allergy to propranolol or alfentanil 9) Any history of drug or alcohol abuse
研究组 & 干预措施
Alfentanil
Experimental inflammation, and tissue injury sites were created, an infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
干预措施: Alfentanil (Drug)
Propranolol
Experimental inflammation and tissue injury sites were created, an infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
干预措施: Propranolol (Drug)
Placebo
Experimental inflammation and tissue injury sites were created, an infusion of normal saline was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in Mechanical Pain Threshold During Infusion in Non-Inflamed Skin
时间窗: Participants underwent the pain testing measures at baseline and at 1 and 2 hours after startingthe drug infusion.
A metal rod of 0.24 mm diameter mounted onto 10 different weights (1.0, 2.0, 4.1, 8.2,16.3, 20, 32.7,49.0, 65.3, and 81.3g) will be placed perpendicularly onto the skin. Starting with the lightest probe, consecutively heavier probes will be used until a subject reports pain. Subsequently, the same or the next lighter probe will be used if pain is reported for the preceding stimulus, or the same or the next heavier probe will be used if no pain is reported for the preceding stimulus.The procedure will be repeated until seven perceptional changes (painful/non-painful) are registered. Measurements for analgesia were taken at the sites of non-injured skin. Change form baseline was calculated by subtracting baseline values from the average values obtained 1 and 2 hours after starting the drug infusion.
Change From Baseline in Heat Pain Threshold During Infusion in Inflamed Skin
时间窗: Participants underwent the pain testing measures at baseline and at 1 and 2 hours after startingthe drug infusion.
Degrees Centigrade Heat pain was induced with a thermal sensory analyzer (TSA-II, Medoc Advanced Medical Systems, Durham, North Carolina). A thermode was placed in contact with skin on the upper thigh. Starting at a comfortable temperature, the thermode temperature was increased at a measured rate. Study participants pushed a button of a hand-held device at the onset of pain at which point the thermode immediately reduced the temperature. Measurements for anti-hyperalgesia were taken at the sites of tissue injury. Change form baseline was calculated by subtracting baseline values from the average values obtained 1 and 2 hours after starting the drug infusion.
Change From Baseline in Heat Pain Threshold During Infusion in Non-Inflamed Skin
时间窗: Participants underwent the pain testing measures at baseline and at 1 and 2 hours after startingthe drug infusion.
Degrees Centigrade Heat pain was induced with a thermal sensory analyzer (TSA-II, Medoc Advanced Medical Systems, Durham, North Carolina). A thermode was placed in contact with skin on the upper thigh. Starting at a comfortable temperature, the thermode temperature was increased at a measured rate. Study participants pushed a button of a hand-held device at the onset of pain at which point the thermode immediately reduced the temperature. Measurements for analgesia were taken at the sites of non-injured skin. Change form baseline was calculated by subtracting baseline values from the average values obtained 1 and 2 hours after starting the drug infusion.
Change From Baseline in Mechanical Pain Threshold During Infusion in Inflamed Skin
时间窗: Participants underwent the pain testing measures at baseline and at 1 and 2 hours after startingthe drug infusion.
A metal rod of 0.24 mm diameter mounted onto 10 different weights (1.0, 2.0, 4.1, 8.2,16.3, 20, 32.7,49.0, 65.3, and 81.3g) will be placed perpendicularly onto the skin. Starting with the lightest probe, consecutively heavier probes will be used until a subject reports pain. Subsequently, the same or the next lighter probe will be used if pain is reported for the preceding stimulus, or the same or the next heavier probe will be used if no pain is reported for the preceding stimulus.The procedure will be repeated until seven perceptional changes (painful/non-painful) are registered. Measurements for anti-hyperalgesia were taken at the sites of tissue injury. Change form baseline was calculated by subtracting baseline values from the average values obtained 1 and 2 hours after starting the drug infusion.
次要结局
- IL-10 (ng/mL) Change From Baseline During Infusion(Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.)
- IL-6 (ng/mL) Change From Baseline During Infusion(Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.)
- GMCSF (ng/mL) Change From Baseline During Infusion(Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.)
- TNFα (ng/mL) Change From Baseline During Infusion(Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.)
- IL-1β (ng/mL) Change From Baseline During Infusion(Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.)
- IL-2 (ng/mL) Change From Baseline During Infusion(Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.)
- IL-8 (ng/mL) Change From Baseline During Infusion(Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.)
- Change in Arbitrary Perfusion Units From Baseline During Drug Infusion(Laser doppler images were recorded at baseline and at 2 and 3 hours after starting the drug infusion)
- IL-12 (ng/mL) Change From Baseline During Infusion(Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.)
研究者
Martin Angst
Professor of Anesthesia
Stanford University